美国生物技术公司Alector周一表示，瑞士制药商罗氏将支付高达12.7亿美元以获得其帕金森病实验性疗法的许可，消息推动其股价在盘前交易中飙升72%。
Swiss drugmaker Roche will pay up to $1.27 billion to license Alector's experimental treatment for Parkinson's disease, the US biotech said on Monday, sending its shares surging 72% in premarket trading.